Natera stock has delivered a very large return over the past three years, yet the valuation checks send a mixed signal, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable discount while market based multiples lean expensive.

• Natera has returned very close to 5x over the past three years, which puts recent gains front and center in any valuation discussion.
• Recent revenue momentum and expanding test adoption can support optimism around long term cash generation, while ongoing losses and the need to keep funding growth may still weigh on how much investors are willing to pay.
• The stock screens as undervalued in only 2 of 6 valuation checks, which suggests Natera is not a straightforward bargain on the broader framework.

The issue now is whether the current share price leaves enough margin between market value and intrinsic value to compensate for the risks in Natera's story.

Is Natera Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model values Natera based on the cash it is expected to generate for shareholders over time. For Natera, the model starts from latest twelve month free cash flow of about $84.3 million and assumes that cash generation continues to grow from this base.

On these cash flow projections, the DCF model points to an estimated intrinsic value of about $606 per share in dollar terms. This implies the stock is roughly 48.7% undervalued versus the current market price. The recent Q2 2026 update showed stronger revenue, higher test volumes and better margins, and the raised full year guidance helps explain why the cash flow outlook embedded in this model is relatively optimistic.

Overall, the Discounted Cash Flow workup suggests Natera stock currently screens as undervalued.

Our Discounted Cash Flow (DCF) analysis suggests Natera is undervalued by 48.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Does Natera Look Pricey on Sales?

P/S is a useful lens for Natera because the company is still loss making, so the revenue base provides a clearer reference point than earnings. On this measure, Natera trades at about 16.5x P/S, which is above the biotech industry average of roughly 11.4x and also above the peer group average of about 10.3x.

The tailored fair P/S ratio for Natera is estimated at around 9.8x. This fair level reflects factors such as the company’s growth profile, margins, scale and risk. The current 16.5x multiple sits materially above that fair ratio, which suggests investors are already paying a premium for Natera’s revenue.

Based on the P/S multiple comparison, Natera stock appears expensive relative to these reference points.

The Natera Narrative: What Would Justify Today's Price?

Simply Wall St Narratives picks up where Natera's valuation puzzle leaves off. Narratives spell out which paths for Natera’s growth, margins and future earnings would need to play out for the stock to be worth materially more or materially less than today’s price. Each one presents fair value as a thesis about the business that you can revisit over time on the company’s Community page.

Natera attracts sharply different views, with some investors seeing a long runway from guideline and regulatory gains while others worry that expectations already sit high.

Bull case: 6% undervalued

"Natera's rapid-fire launch strategy and unmatched scale in clinical trials, including over $150 million invested and 18 peer-reviewed publications in breast cancer alone, position the company to decisively outflank competitors."

Bear case: 10% overvalued

"High and growing R&D and SG&A expenses, including major investments in new trials, expanded commercial team, and AI initiatives, may create persistent pressure on net margins and delay pathway to sustainable profitability."

Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!

The Bottom Line

Natera’s Discounted Cash Flow (DCF) work points to a large intrinsic value gap, while revenue based multiples suggest the stock is already priced at a premium. That split largely reflects the tension between long term cash flow potential on one side and high expectations embedded in today’s P/S multiple on the other. The broader valuation checks remain weak, which means investors are leaning on a single optimistic signal rather than a consistent picture. The key question from here is whether Natera can convert test adoption and revenue momentum into durable margins fast enough to justify both the intrinsic value estimate and the current premium pricing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.